Cancer nanomedicine: Progress, challenges and opportunities

Nature Reviews Cancer

Volumn 17, Issue 1, 2017, Pages 20-37

  Shi, Jinjun ^a   Kantoff, Philip W ^b   Wooster, Richard ^c   Farokhzad, Omid C ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Medicinal Chemistry   (United States)

^d KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NANOCARRIER; NANOPARTICLE; PROTEIN;

CANCER PATIENT; CANCER THERAPY; CELL MIGRATION; CELLULAR UPTAKE; CHEMICAL INTERACTION; CIRCULATION; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG EXTRAVASATION; DRUG PENETRATION; DRUG TARGETING; ENHANCED PERMEABILITY AND RETENTION EFFECT; EVALUATION STUDY; GOOD MANUFACTURING PRACTICE; HUMAN; METASTASIS; MULTICENTER STUDY (TOPIC); NANOMEDICINE; NANOPHARMACEUTICS; NEOPLASM; NONHUMAN; ONCOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL PARAMETERS; PHYSICAL PHENOMENA; PREMETASTATIC NICHE; PRIORITY JOURNAL; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCALE UP; SCREENING; SYNTHESIS; SYSTEMATIC REVIEW (TOPIC); TRANSPORT AT THE CELLULAR LEVEL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; NANOTECHNOLOGY; NEOPLASMS; PROCEDURES;

HUMANS; NANOMEDICINE; NANOTECHNOLOGY; NEOPLASMS;

EID: 84994713359     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.108     Document Type: Review

References (297)

1. Ferrari, M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5, 161-171 (2005
2. Peer, D., et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007
3. Shi, J., Votruba, A R., Farokhzad, O. C., & Langer, R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 10, 3223-3230 (2010
4. Swartz, M. A., Hirosue, S., & Hubbell, J. A. Engineering approaches to immunotherapy. Sci. Transl Med. 4, 148rv9 (2012
5. Kearney, C. J., & Mooney, D. J. Macroscale delivery systems for molecular and cellular payloads. Nat. Mater. 12, 1004-1017 (2013
6. Smith, A. D. Big moment for nanotech: oncology therapeutics poised for a leap. OncLive http://www. onclive.com/publications/Oncology-live/2013/June-2013/Big-Moment-for-Nanotech-Oncology-Therapeutics-Poised-for-A-Leap (2013
7. Matsumura, Y., & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392 (1986
8. Gerlowski, L. E., & Jain, R. K. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31, 288-305 (1986
9. Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 66, 2-25 (2014
10. Maeda, H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Deliv. Rev. 91, 3-6 (2015
11. Hrkach, J., et al. Preclinical development and clinical translation of a PSMA-Targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl Med. 4, 128ra39 (2012
12. Eliasof, S., et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc. Natl Acad. Sci. USA 110, 15127-15132 (2013
13. Zuckerman, J. E., et al. Correlating animal and human phase Ia/Ib clinical data with CALAA 01, a targeted, polymer-based nanoparticle containing siRNA. Proc. Natl Acad. Sci. USA 111, 11449-11454 (2014
14. Joyce, J. A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 7, 513-520 (2005
15. Meads, M. B., Gatenby, R. A., & Dalton, W. S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 9, 665-674 (2009
16. Barenholz, Y. Doxil®-The first FDA-Approved nano-drug: lessons learned. J. Control. Release 160, 117-134 (2012
17. Petersen, G. H., Alzghari, S. K., Chee, W., Sankari, S. S., & La Beck, N. M. Meta-Analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J. Control. Release 232, 255-264 (2016
18. Celator Pharmaceuticals, Inc. Celator announces phase 3 trial for VYXEOS™ (CPX 351) in patients with high-risk acute myeloid leukemia demonstrates statistically significant improvement in overall survival. prnewswire http://www.prnewswire.com/news-releases/celator-Announces-phase-3-Trial-for-vyxeos-cpx-351-in-patients-with-high-risk-Acute-myeloid-leukemia-demonstrates-statistically-significant-improvement-in-overall-survival-300235620.html (2016
19. Gradishar, W. J., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803 (2005
20. Rugo, H. S., et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J. Clin. Oncol. 33, 2361-2369 (2015
21. Ahn, H. K., et al. A phase II trial of Cremorphor EL free paclitaxel (Genexol PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 74, 277-282 (2014
22. Kato, K., et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. New Drugs 30, 1621-1627 (2012
23. Clark, A. J., et al. CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. Proc. Natl Acad. Sci. USA 113, 3850-3854 (2016
24. Ashton, S., et al. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci. Transl Med. 8, 325ra17 (2016
25. Hirsch, L. R., et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl Acad. Sci. USA 100, 13549-13554 (2003
26. Maier-Hauff, K., et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 103, 317-324 (2011
27. Maggiorella, L., et al. Nanoscale radiotherapy with hafnium oxide nanoparticles. Future Oncol. 8, 1167-1181 (2012
28. Dritschilo, A., et al. Phase I study of liposome-encapsulated c raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin. Cancer Res. 12, 1251-1259 (2006
29. Elazar, V., et al. Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. Int. J. Cancer 126, 1749-1760 (2010
30. Davis, M. E., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010
31. Tabernero, J., et al. First in humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3, 406-417 (2013
32. Schultheis, B., et al. First in human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J. Clin. Oncol. 32, 4141-4148 (2014
33. Jensen, S. A., et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci. Transl Med. 5, 209ra152 (2013
34. Islam, M. A., et al. Biomaterials for mRNA delivery. Biomater. Sci. 3, 1519-1533 (2015
35. Tolcher, A. W., et al. A phase 1 study of the BCL2 targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 73, 363-371 (2014
36. Yildiz, I., Shukla, S., & Steinmetz, N. F. Applications of viral nanoparticles in medicine. Curr. Opin. Biotechnol. 22, 901-908 (2011
37. Yla-Herttuala, S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol. Ther. 20, 1831-1832 (2012
38. Naldini, L. Gene therapy returns to centre stage. Nature 526, 351-360 (2015
39. Shukla, S., DiFranco, N. A., Wen, A. M., Commandeur, U., & Steinmetz, N. F. To target or not to target: active versus passive tumor homing of filamentous nanoparticles based on potato virus X. Cell. Mol. Bioeng. 8, 433-444 (2015
40. Czapar, A. E., et al. Tobacco mosaic virus delivery of phenanthriplatin for cancer therapy. ACS Nano 10, 4119-4126 (2016
41. Batrakova, E. V., & Kim, M. S. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J. Control. Release 219, 396-405 (2015
42. Chow, E. K., et al. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci. Transl Med. 3, 73ra21 (2011
43. Mochalin, V. N., et al. Adsorption of drugs on nanodiamond: toward development of a drug delivery platform. Mol. Pharm. 10, 3728-3735 (2013
44. Jiang, T., et al. Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene. Adv. Mater. 27, 1021-1028 (2015
45. Liu, Z., Robinson, J. T., Sun, X., & Dai, H. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J. Am. Chem. Soc. 130, 10876-10877 (2008
46. Choi, K. Y., Liu, G., Lee, S., & Chen, X. Theranostic nanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale 4, 330-342 (2012
47. Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., & Tsourkas, A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 338, 903-910 (2012
48. Smith, D. M., Simon, J. K., & Baker, J. R. Jr. Applications of nanotechnology for immunology. Nat. Rev. Immunol. 13, 592-605 (2013
49. Irvine, D. J., Swartz, M. A., & Szeto, G. L. Engineering synthetic vaccines using cues from natural immunity. Nat. Mater. 12, 978-990 (2013
50. Rosenthal, J. A., Chen, L., Baker, J. L., Putnam, D., & DeLisa, M. P. Pathogen-like particles: biomimetic vaccine carriers engineered at the nanoscale. Curr. Opin. Biotechnol. 28, 51-58 (2014
51. Schellekens, H. The immunogenicity of therapeutic proteins. Discov. Med. 9, 560-564 (2010
52. Kishimoto, T. K., et al. Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. Nat. Nanotechnol. http://dx.doi.org/10.1038/ nnano.2016.1135 (2016
53. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/ NCT02648269?term (2016
54. Garbuzenko, O. B., et al. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc. Natl Acad. Sci. USA 107, 10737-10742 (2010
55. Liechty, W. B., Caldorera-Moore, M., Phillips, M. A., Schoener, C., & Peppas, N. A. Advanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics. J. Control. Release 155, 119-127 (2011
56. Yu, M., Wu, J., Shi, J., & Farokhzad, O. C. Nanotechnology for protein delivery: overview and perspectives. J. Control. Release http://dx.doi. org/10.1016/j.jconrel.2015.1010.1012 (2015
57. Ramanathan, R. K., et al. Pilot study in patients with advanced solid tumors to evaluate feasibility of ferumoxytol (FMX) as tumor imaging agent prior to MM398, a nanoliposomal irinotecan (nalIRI). Cancer Res. 74 (Suppl.), abstr. CT224 (2014
58. Koukourakis, M. I., et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J. Clin. Oncol. 17, 3512-3521 (1999
59. Arrieta, O., et al. High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin. Cancer Chemother. Pharmacol. 74, 211-215 (2014
60. Daldrup-Link, H. E., et al. MRI of tumor-Associated macrophages with clinically applicable iron oxide nanoparticles. Clin. Cancer Res. 17, 5695-5704 (2011
61. Kalra, A. V., et al. Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM 398, a nanoliposomal irinotecan (nal-IRI). Cancer Res. 74 (Suppl.), 2065 (2014
62. Miller, M. A., et al. Tumour-Associated macrophages act as a slow-release reservoir of nano-Therapeutic Pt(IV) pro-drug. Nat. Commun. 6, 8692 (2015
63. Miller, M. A., et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Sci. Transl Med. 7, 314ra183 (2015
64. Bashir, M. R., Bhatti, L., Marin, D., & Nelson, R. C. Emerging applications for ferumoxytol as a contrast agent in MRI. J. Magn. Reson. Imaging 41, 884-898 (2015
65. Farokhzad, O. C., et al. Targeted nanoparticle-Aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103, 6315-6320 (2006
66. Gu, F., et al. Precise engineering of targeted nanoparticles by using self-Assembled biointegrated block copolymers. Proc. Natl Acad. Sci. USA 105, 2586-2591 (2008
67. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01770353?term (2016
68. Harrington, K. J., et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 7, 243-254 (2001
69. Koukourakis, M. I., et al. High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br. J. Cancer 83, 1281-1286 (2000
70. Seymour, L. W., et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20, 1668-1676 (2002
71. Lee, H., et al. A gradient-loadable 64Cu chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography. Nanomedicine 11, 155-165 (2015
72. Hansen, A. E., et al. Positron emission tomography based elucidation of the enhanced permeability and retention effect in dogs with cancer using copper 64 liposomes. ACS Nano 9, 6985-6995 (2015
73. Yokoi, K., et al. Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. Cancer Lett. 345, 48-55 (2014
74. Yokoi, K., et al. Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. Cancer Res. 74, 4239-4246 (2014
75. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971
76. Sessa, C., Guibal, A., Del Conte, G., & Ruegg, C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat. Clin. Pract. Oncol. 5, 378-391 (2008
77. Cedervall, T., et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl Acad. Sci. USA 104, 2050-2055 (2007
78. Nel, A. E., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8, 543-557 (2009
79. Mahmoudi, M., et al. Protein-nanoparticle interactions: opportunities and challenges. Chem. Rev. 111, 5610-5637 (2011
80. Monopoli, M. P., Aberg, C., Salvati, A., & Dawson, K. A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7, 779-786 (2012
81. Salvador-Morales, C., Zhang, L., Langer, R., & Farokhzad, O. C. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 30, 2231-2240 (2009)
82. Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 134, 2139-2147 (2012
83. Ritz, S., et al. Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. Biomacromolecules 16, 1311-1321 (2015
84. Ogawara, K., et al. Pre-coating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanosphere: implications for rational design of nanoparticles. J. Control. Release 100, 451-455 (2004
85. Salvati, A., et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 8, 137-143 (2013
86. Dong, Y., et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl Acad. Sci. USA 111, 3955-3960 (2014
87. Chanan-Khan, A., et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 14, 1430-1437 (2003
88. Walkey, C. D., & Chan, W. C. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41, 2780-2799 (2012
89. Walkey, C. D., et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 8, 2439-2455 (2014
90. Bigdeli, A., et al. Exploring cellular interactions of liposomes using protein corona fingerprints and physicochemical properties. ACS Nano 10, 3723-3737 (2016
91. Hajipour, M. J., Laurent, S., Aghaie, A., Rezaee, F., & Mahmoudi, M. Personalized protein coronas: a key factor at the nanobiointerface. Biomater. Sci. 2, 1210-1221 (2014
92. Sakulkhu, U., et al. Ex situ evaluation of the composition of protein corona of intravenously injected superparamagnetic nanoparticles in rats. Nanoscale 6, 11439-11450 (2014
93. Gref, R., et al. Biodegradable long-circulating polymeric nanospheres. Science 263, 1600-1603 (1994
94. Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. 49, 6288-6308 (2010
95. Gabizon, A., Shmeeda, H., & Barenholz, Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42, 419-436 (2003
96. Schottler, S., et al. Protein adsorption is required for stealth effect of poly(ethylene glycol)-And poly(phosphoester)-coated nanocarriers. Nat. Nanotechnol. 11, 372-377 (2016
97. Key, J., et al. Soft discoidal polymeric nanoconstructs resist macrophage uptake and enhance vascular targeting in tumors. ACS Nano 9, 11628-11641 (2015
98. Anselmo, A. C., et al. Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting. ACS Nano 9, 3169-3177 (2015
99. Rodriguez, P. L., et al. Minimal self peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339, 971-975 (2013
100. Hu, C. M., et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108, 10980-10985 (2011
101. Parodi, A., et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat. Nanotechnol. 8, 61-68 (2013
102. Hu, C. M., et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526, 118-121 (2015
103. Hu, Q., et al. Anticancer platelet-mimicking nanovehicles. Adv. Mater. 27, 7043-7050 (2015
104. Hobson, B., & Denekamp, J. Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br. J. Cancer 49, 405-413 (1984
105. Nourshargh, S., & Alon, R. Leukocyte migration into inflamed tissues. Immunity 41, 694-707 (2014
106. Ashina, K., et al. Histamine induces vascular hyperpermeability by increasing blood flow and endothelial barrier disruption in vivo. PLoS ONE 10, e0132367 (2015
107. Maeda, H., Nakamura, H., & Fang, J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 65, 71-79 (2013
108. Deli, M. A. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim. Biophys. Acta 1788, 892-910 (2009
109. Thurber, G. M., & Weissleder, R. A systems approach for tumor pharmacokinetics. PLoS ONE 6, e24696 (2011
110. Matsumoto, Y., et al. Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat. Nanotechnol. 11, 533-538 (2016
111. Seki, T., Fang, J., & Maeda, H. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci. 100, 2426-2430 (2009
112. Cabral, H., et al. Accumulation of sub 100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6, 815-823 (2011
113. Park, J. H., et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv. Mater. 20, 1630-1635 (2008
114. Chauhan, V. P., et al. Fluorescent nanorods and nanospheres for real-Time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew. Chem. Int. Ed. 50, 11417-11420 (2011
115. Gentile, F., et al. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J. Biomech. 41, 2312-2318 (2008
116. Kolhar, P., et al. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc. Natl Acad. Sci. USA 110, 10753-10758 (2013
117. Smith, B R., et Al. Shape Matters: Intravital Microscopy Reveals Surprising Geometrical Dependence for Nanoparticles in Tumor Models of Extravasation. Nano Lett. 12, 3369-3377 (2012
118. Cheng, H., et al. Nanoparticulate cellular patches for cell-mediated tumoritropic delivery. ACS Nano 4, 625-631 (2010
119. Roger, M., et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials 31, 8393-8401 (2010
120. Choi, M R., et Al. A Cellular Trojan Horse for Delivery of Therapeutic Nanoparticles into Tumors. Nano Lett. 7, 3759-3765 (2007
121. Alizadeh, D., Zhang, L., Hwang, J., Schluep, T., & Badie, B. Tumor-Associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas. Nanomedicine 6, 382-390 (2010
122. von Maltzahn, G., et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat. Mater. 10, 545-552 (2011
123. Dreher, M. R., et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl Cancer Inst. 98, 335-344 (2006
124. Rudnick, S. I., et al. Influence of affinity and antigen internalization on the uptake and penetration of anti HER2 antibodies in solid tumors. Cancer Res. 71, 2250-2259 (2011
125. Jain, R. K., & Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653-664 (2010
126. Jain, R. K., & Baxter, L. T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48, 7022-7032 (1988
127. Awwad, H. K., el Naggar, M., Mocktar, N., & Barsoum, M. Intercapillary distance measurement as an indicator of hypoxia in carcinoma of the cervix uteri. Int. J. Radiat. Oncol. Biol. Phys. 12, 1329-1333 (1986
128. Yoshii, Y., & Sugiyama, K. Intercapillary distance in the proliferating area of human glioma. Cancer Res. 48, 2938-2941 (1988
129. West, C. M., Cooper, R. A., Loncaster, J. A., Wilks, D. P., & Bromley, M. Tumor vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res. 61, 2907-2910 (2001
130. Wong, C., et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl Acad. Sci. USA 108, 2426-2431 (2011
131. Chauhan, V. P., et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7, 383-388 (2012
132. Tong, R., Chiang, H. H., & Kohane, D. S. Photoswitchable nanoparticles for in vivo cancer chemotherapy. Proc. Natl Acad. Sci. USA 110, 19048-19053 (2013
133. Sugahara, K. N., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16, 510-520 (2009
134. Ren, Y., et al. Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci. Transl Med. 4, 147ra112 (2012
135. Pittet, M. J., & Weissleder, R. Intravital imaging. Cell 147, 983-991 (2011
136. Chauhan, V. P., & Jain, R. K. Strategies for advancing cancer nanomedicine. Nat. Mater. 12, 958-962 (2013
137. Bilodeau, M. T., et al. Pentarins: improved tumor targeting through nanoparticle encapsulation of miniaturized biologic drug conjugates. Cancer Res. 75 (Suppl), abstr. 3674 (2015
138. Vlahov, I. R., & Leamon, C. P. Engineering folate-drug conjugates to target cancer: from chemistry to clinic. Bioconjug. Chem. 23, 1357-1369 (2012
139. Firer, M. A., & Gellerman, G. Targeted drug delivery for cancer therapy: the other side of antibodies. J. Hematol. Oncol. 5, 70 (2012
140. Tasciotti, E., et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol. 3, 151-157 (2008
141. Xu, R., et al. An injectable nanoparticle generator enhances delivery of cancer therapeutics. Nat. Biotechnol. 34, 414-418 (2016
142. Li, H. J., et al. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc. Natl Acad. Sci. USA 113, 4164-4169 (2016
143. Whitehead, K. A., Langer, R., & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129-138 (2009
144. Davis, M. E. The first targeted delivery of siRNA in humans via a self-Assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6, 659-668 (2009
145. Zhu, X., et al. Long-circulating siRNA nanoparticles for validating prohibitin1 targeted non-small cell lung cancer treatment. Proc. Natl Acad. Sci. USA 112, 7779-7784 (2015
146. Shi, J., Xiao, Z., Kamaly, N., & Farokhzad, O. C. Self-Assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc. Chem. Res. 44, 1123-1134 (2011
147. Farokhzad, O. C., & Langer, R. Impact of nanotechnology on drug delivery. ACS Nano 3, 16-20 (2009
148. Howard, M., et al. Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano 8, 4100-4132 (2014
149. Pridgen, E. M., et al. Transepithelial transport of Fc targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci. Transl Med. 5, 213ra167 (2013
150. Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., & Lesniak, M. S. Multifunctional nanoparticles for brain tumor imaging and therapy. Adv. Drug Deliv. Rev. 66, 42-57 (2014
151. Zhu, X., et al. Polymeric nanoparticles amenable to simultaneous installation of exterior targeting and interior therapeutic proteins. Angew. Chem. Int. Ed. 55, 3309-3312 (2016
152. Leserman, L D., Barbet, J., Kourilsky, F., & Weinstein, J. N. Targeting to Cells of Fluorescent Liposomes Covalently Coupled with Monoclonal Antibody or Protein A. Nature 288, 602-604 (1980
153. Heath, T. D., Fraley, R. T., & Papahdjopoulos, D. Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab')2 to vesicle surface. Science 210, 539-541 (1980
154. Espelin, C. W., Leonard, S. C., Geretti, E., Wickham, T. J., & Hendriks, B. S. Dual HER2 targeting with trastuzumab and liposomal-encapsulated doxorubicin (MM 302) demonstrates synergistic antitumor activity in breast and gastric cancer. Cancer Res. 76, 1517-1527 (2016
155. Gratton, S. E., et al. The effect of particle design on cellular internalization pathways. Proc. Natl Acad. Sci. USA 105, 11613-11618 (2008
156. Chithrani, B D., Ghazani, A. A., & Chan, W. C. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6, 662-668 (2006
157. Commisso, C., et al. Macropinocytosis of protein is an amino acid supply route in Ras-Transformed cells. Nature 497, 633-637 (2013
158. Narayanan, V., & Weekes, C. D. Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma. Gastrointest. Cancer 5, 11-19 (2015
159. Thurber, G. M., et al. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat. Commun. 4, 1504 (2013
160. Chittajallu, D. R., et al. In vivo cell-cycle profiling in xenograft tumors by quantitative intravital microscopy. Nat. Methods 12, 577-585 (2015
161. Laughney, A. M., et al. Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin. Sci. Transl Med. 6, 261ra152 (2014
162. Dubach, J. M., et al. In vivo imaging of specific drug-Target binding at subcellular resolution. Nat. Commun. 5, 3946 (2014
163. Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. Delivery materials for siRNA therapeutics. Nat. Mater. 12, 967-977 (2013
164. Ozpolat, B., Sood, A. K., & Lopez-Berestein, G. Liposomal siRNA nanocarriers for cancer therapy. Adv. Drug Deliv. Rev. 66, 110-116 (2014
165. Zuckerman, J. E., & Davis, M. E. Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat. Rev. Drug Discov. 14, 843-856 (2015
166. Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. Nanoparticles modified with tumor-Targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 18, 1650-1656 (2010
167. Gilleron, J., et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638-646 (2013
168. Sahay, G., et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol. 31, 653-658 (2013
169. Xu, Z. P., et al. Subcellular compartment targeting of layered double hydroxide nanoparticles. J. Control. Release 130, 86-94 (2008
170. Cheng, F. Y., et al. Stabilizer-free poly(lactide-co glycolide) nanoparticles for multimodal biomedical probes. Biomaterials 29, 2104-2112 (2008
171. Boddapati, S. V., et al. Mitochondriotropic liposomes. J. Liposome Res. 15, 49-58 (2005
172. Boddapati, S V., D'Souza, G. G., Erdogan, S., Torchilin, V. P., & Weissig, V. Organelle-Targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett. 8, 2559-2563 (2008
173. Marrache, S., & Dhar, S. Engineering of blended nanoparticle platform for delivery of mitochondria-Acting therapeutics. Proc. Natl Acad. Sci. USA 109, 16288-16293 (2012
174. Yameen, B., et al. Insight into nanoparticle cellular uptake and intracellular targeting. J. Control. Release 190, 485-499 (2014
175. Kalra, A. V., et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 74, 7003-7013 (2014
176. Koizumi, F., et al. Novel SN 38 incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 66, 10048-10056 (2006
177. Nakajima, T. E., et al. Antitumor effect of SN 38 releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan. Cancer Res. 68, 9318-9322 (2008
178. Hamaguchi, T., et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer 92, 1240-1246 (2005
179. Mura, S., Nicolas, J., & Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 12, 991-1003 (2013
180. Xu, X., et al. Ultra pH responsive and tumor-penetrating nanoplatform for targeted siRNA delivery with robust anti-cancer efficacy. Angew. Chem. Int. Ed. 55, 7091-7094 (2016
181. Wu, J., et al. Hydrophobic cysteine poly(disulfide)-based redox-hypersensitive nanoparticle platform for cancer theranostics. Angew. Chem. Int. Ed. 54, 9218-9223 (2015
182. Wang, Y., et al. A nanoparticle-based strategy for the imaging of a broad range of tumours by nonlinear amplification of microenvironment signals. Nat. Mater. 13, 204-212 (2014
183. Paris, J. L., Cabanas, M. V., Manzano, M., & Vallet-Regi, M. Polymer-grafted mesoporous silica nanoparticles as ultrasound-responsive drug carriers. ACS Nano 9, 11023-11033 (2015
184. He, Q., et al. NIR-responsive on demand release of CO from metal carbonyl-caged graphene oxide nanomedicine. Adv. Mater. 27, 6741-6746 (2015
185. Quail, D. F., & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423-1437 (2013
186. Psaila, B., & Lyden, D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 9, 285-293 (2009
187. Neri, D., & Bicknell, R. Tumour vascular targeting. Nat. Rev. Cancer 5, 436-446 (2005
188. Murphy, E. A., et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl Acad. Sci. USA 105, 9343-9348 (2008
189. Hood, J. D., et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296, 2404-2407 (2002
190. Santel, A., et al. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther. 13, 1360-1370 (2006
191. Fehring, V., et al. Delivery of therapeutic siRNA to the lung endothelium via novel lipoplex formulation DACC. Mol. Ther. 22, 811-820 (2014
192. Dahlman, J. E., et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat. Nanotechnol. 9, 648-655 (2014
193. Murakami, M., et al. Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res. 73, 4862-4871 (2013
194. Mantovani, A., & Sica, A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22, 231-237 (2010
195. Zhang, X., et al. Hydrazinocurcumin encapsuled nanoparticles re educate tumor-Associated macrophages and exhibit anti-Tumor effects on breast cancer following STAT3 suppression. PLoS ONE 8, e65896 (2013
196. Zhu, S., Niu, M., O'Mary, H., & Cui, Z. Targeting of tumor-Associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol. Pharm. 10, 3525-3530 (2013
197. Sengupta, S., et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436, 568-572 (2005
198. Guo, S., et al. Co delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 8, 4996-5009 (2014
199. Park, J., et al. Combination delivery of TGF-β inhibitor and IL 2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat. Mater. 11, 895-905 (2012
200. Mueller, M. M., & Fusenig, N. E. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4, 839-849 (2004
201. Schroeder, A., et al. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 12, 39-50 (2012
202. Tsukigawa, K., et al. Synthesis and therapeutic effect of styrene-maleic acid copolymer-conjugated pirarubicin. Cancer Sci. 106, 270-278 (2015
203. Dozono, H., et al. HPMA copolymer-conjugated pirarubicin in multimodal treatment of a patient with stage IV prostate cancer and extensive lung and bone metastases. Target. Oncol. 11, 101-106 (2016
204. Swami, A., et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc. Natl Acad. Sci. USA 111, 10287-10292 (2014
205. Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505-515 (2008
206. Perrault, S D., Walkey, C., Jennings, T., Fischer, H. C., & Chan, W. C. Mediating Tumor Targeting Efficiency of Nanoparticles Through Design. Nano Lett. 9, 1909-1915 (2009
207. Karnik, R., et al Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett. 8, 2906-2912 (2008
208. Valencia, P. M., et al. Single-step assembly of homogenous lipid-polymeric and lipid-quantum dot nanoparticles enabled by microfluidic rapid mixing. ACS Nano 4, 1671-1679 (2010
209. Rhee, M., et al. Synthesis of size-Tunable polymeric nanoparticles enabled by 3D hydrodynamic flow focusing in single-layer microchannels. Adv. Mater. 23, H79-H83 (2011
210. Chen, D., et al. Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J. Am. Chem. Soc. 134, 6948-6951 (2012
211. Kim, Y., et al Mass production and size control of lipid-polymer hybrid nanoparticles through controlled microvortices. Nano Lett. 12, 3587-3591 (2012
212. Rolland, J. P., et al. Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J. Am. Chem. Soc. 127, 10096-10100 (2005
213. Xu, J., et al. Future of the particle replication in nonwetting templates (PRINT) technology. Angew. Chem. Int. Ed. 52, 6580-6589 (2013
214. Toh, Y. C., et al. A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab Chip 9, 2026-2035 (2009
215. Huh, D., et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662-1668 (2010
216. Albanese, A., Lam, A. K., Sykes, E. A., Rocheleau, J. V., & Chan, W. C. Tumour-on a chip provides an optical window into nanoparticle tissue transport. Nat. Commun. 4, 2718 (2013
217. Choi, S. Y., et al. Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv. Drug Deliv. Rev. 79-80, 222-237 (2014
218. Sharpless, N. E., & Depinho, R. A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5, 741-754 (2006
219. Lin, D., et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 74, 1272-1283 (2014
220. Rongvaux, A., et al. Development and function of human innate immune cells in a humanized mouse model. Nat. Biotechnol. 32, 364-372 (2014
221. Hubbard, G. K., et al. Combined MYC activation and Pten loss are sufficient to create genomic instability and lethal metastatic prostate cancer. Cancer Res. 76, 283-292 (2016
222. Lim, J. M., et al. Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer. ACS Nano 8, 6056-6065 (2014
223. Bangham, A. D., & Horne, R. W. Negative staining of phospholipids and their structural modification by surface-Active agents as observed in the electron microscope. J. Mol. Biol. 8, 660-668 (1964
224. Folkman, J., & Long, D. M. The use of silicone rubber as a carrier for prolonged drug therapy. J. Surg. Res. 4, 139-142 (1964
225. Langer, R., & Folkman, J. Polymers for the sustained release of proteins and other macromolecules. Nature 263, 797-800 (1976
226. Samyang Biopharm. History. SamyangBiopharm https://www.samyangbiopharm.com/eng/Aboutus/ history (2016
227. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00689065?term (2013
228. MagForce. MagForce Nanotechnologies AG receives European regulatory approval for its Nano Cancer® therapy. magforce.de http://www.magforce.de/en/ presse-investoren/news-events/detail/article/magforce-nanotechnologies-Ag-erhaelt-europaeische-zulassung-fuer-die-nano-krebsR-Therapie.html (2010
229. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01300533?term (2016
230. Inman, S. FDA approves second-line MM 398 regimen for metastatic pancreatic cancer. OncLive http://www. onclive.com/web-exclusives/fda-Approves-mm-398-regimen-for-metastatic-pancreatic-cancer (2015
231. Stathopoulos, G. P., et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann. Oncol. 21, 2227-2232 (2010
232. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01644890?term (2016
233. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00377936?term (2008
234. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00542048?term (2010
235. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01537536?term (2013
236. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00448305?term (2012
237. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02494570?term (2016
238. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02646319?term (2016
239. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01380769?term (2015
240. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02187302?term (2016
241. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01652079?term (2014
242. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02213744?term (2016
243. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01792479?term (2016
244. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02283320?term (2016
245. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01812746?term (2016
246. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00964080?term (2014
247. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01702129?term (2014
248. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02112656?term (2016
249. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01696084?term (2016
250. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00361842?term (2016
251. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00848042?term (2016
252. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01679470?term (2015
253. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02379845?term (2016
254. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02340156?term (2016
255. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02340117?term (2016
256. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01733238?term (2016
257. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02226965?term (2016
258. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01435720?term (2014
259. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01808638?term (2016
260. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01262235?term (2015
261. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02191878?term (2016
262. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02314052?term (2016
263. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01829971?term (2016
264. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00882180?term (2011
265. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01158079?term (2012
266. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01591356?term (2016
267. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01505153?term (2016
268. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00409188?term (2015
269. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00952692?term (2012
270. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01095848?term (2015
271. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01052142?term (2012
272. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00860522?term (2014
273. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00356980?term (2012
274. Tardi, P. G., et al. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol. Cancer Ther. 8, 2266-2275 (2009
275. Zhang, Y. F., Wang, J. C., Bian, D. Y., Zhang, X., & Zhang, Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur. J. Pharm. Biopharm. 74, 467-473 (2010
276. Shim, G., et al. Trilysinoyl oleylamide-based cationic liposomes for systemic co delivery of siRNA and an anticancer drug. J. Control. Release 155, 60-66 (2011
277. Xu, Z., et al. The characteristics and performance of a multifunctional nanoassembly system for the co delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model. Biomaterials 31, 916-922 (2010
278. Yang, Y., et al. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol. Pharm. 9, 2280-2289 (2012
279. Ko, Y. T., Falcao, C., & Torchilin, V. P. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)2 and Bcl 2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol. Pharm. 6, 971-977 (2009
280. Lv, S., et al. Co delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials 35, 6118-6129 (2014
281. Duan, X., et al. Smart pH sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 7, 5858-5869 (2013
282. Tang, S., et al. Inhibition of metastasis and growth of breast cancer by pH sensitive poly (β-Amino ester) nanoparticles co delivering two siRNA and paclitaxel. Biomaterials 48, 1-15 (2015
283. Ediriwickrema, A., Zhou, J., Deng, Y., & Saltzman, W. M. Multi-layered nanoparticles for combination gene and drug delivery to tumors. Biomaterials 35, 9343-9354 (2014
284. Wang, Y., Gao, S., Ye, W. H., Yoon, H. S., & Yang, Y. Y. Co delivery of drugs and DNA from cationic core-shell nanoparticles self-Assembled from a biodegradable copolymer. Nat. Mater. 5, 791-796 (2006
285. Lee, S. J., et al. Co delivery of VEGF and Bcl 2 dual-Targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo. J. Control. Release 220, 631-641 (2015
286. Devulapally, R., et al. Polymer nanoparticles mediated codelivery of antimiR 10b and antimiR 21 for achieving triple negative breast cancer therapy. ACS Nano 9, 2290-2302 (2015
287. Xu, X., et al. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc. Natl Acad. Sci. USA 110, 18638-18643 (2013
288. Deng, Z. J., et al. Layer by layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano 7, 9571-9584 (2013
289. Jiang, T., Mo, R., Bellotti, A., Zhou, J., & Gu, Z. Gel-liposome-mediated co delivery of anticancer membrane-Associated proteins and small-molecule drugs for enhanced therapeutic efficacy. Adv. Funct. Mater. 24, 2295-2304 (2014
290. Zheng, M., et al. Single-step assembly of DOX/ICG loaded lipid-polymer nanoparticles for highly effective chemo-photothermal combination therapy. ACS Nano 7, 2056-2067 (2013
291. Werner, M. E., et al. Folate-Targeted nanoparticle delivery of chemo-And radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials 32, 8548-8554 (2011
292. Han, L., et al. Plasmid pORF-hTRAIL and doxorubicin co delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials 32, 1242-1252 (2011
293. Lee, I. H., et al. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J. Control. Release 155, 435-441 (2011
294. Fang, J. H., et al. Magnetic core-shell nanocapsules with dual-Targeting capabilities and co delivery of multiple drugs to treat brain gliomas. Adv. Healthc. Mater. 3, 1250-1260 (2014
295. Wang, L., et al. Synergistic anticancer effect of RNAi and photothermal therapy mediated by functionalized single-walled carbon nanotubes. Biomaterials 34, 262-274 (2013
296. Xiao, Z., et al. DNA self-Assembly of targeted near-infrared-responsive gold nanoparticles for cancer thermo-chemotherapy. Angew. Chem. Int. Ed. 51, 11853-11857 (2012
297. Liu, T., et al. Drug delivery with PEGylated MoS2 nano-sheets for combined photothermal and chemotherapy of cancer. Adv. Mater. 26, 3433-3440 (2014